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Abstract The prevalence of type 2 diabetes mellitus is high among the elderly pop-
ulation. Treatment of elderly patients with type 2 diabetes presents challenges
because of co-morbidities and the potential increase in the risk of adverse
effects. Hyperlipidaemia is also common in the elderly population. Glucose-
and lipid-lowering treatment in elderly patients should be individualized on
the basis of the patient’s life expectancy, health status and cardiovascular risk
factors, and evidence-based guideline recommendations. Because elderly pa-
tients often have impaired renal and hepatic function, careful considerations
must be made when selecting appropriate glucose- and lipid-lowering ther-
apy. There are a number of potential safety issues associated with various
glucose- and lipid-lowering therapies that are relevant to elderly patients,
including increased risk of heart failure exacerbations, weight loss, increased
risk of hypoglycaemia, increased risk of myopathy, and contraindications of
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some agents in patients with hepatic or renal impairment. The bile acid se-
questrant colesevelam HCl is unique compared with other glucose- and lipid-
lowering therapies because it is the only product approved by the US Food
and Drug Administration, as an adjunct to diet and exercise, to lower both
glucose and low-density lipoprotein cholesterol (LDL-C) in adults with type 2
diabetes and primary hyperlipidaemia, respectively. Furthermore, coleseve-
lam has been shown to have similar glucose- and lipid-lowering efficacy in
patients aged <65 years and those aged ‡65 years. Colesevelam was not as-
sociated with weight gain, was associated with a low incidence of hypogly-
caemia, and can be safely combined with a broad range of glucose-lowering
agents (metformin, sulfonylureas and insulin) and lipid-lowering statins.
Currently, colesevelam is available in tablet form and as a powder for oral
suspension formulation; the latter may be of benefit to elderly patients with
swallowing difficulties. As colesevelam has both glucose- and lipid-lowering
effects, its use may reduce the drug burden in elderly patients receiving mul-
tiple agents for glucose and lipid lowering. Colesevelam may be a valuable
treatment option as an add-on to existing glucose- and/or lipid-lowering ther-
apy to help improve haemoglobin A1c and to lower LDL-C levels in elderly
patients with type 2 diabetes and primary hyperlipidaemia.
1. Introduction
Diabetes mellitus is a chronic disease charac-
terized by persistent hyperglycaemia, which is as-
sociated with increased morbidity and mortality.[1]
Globally, the age-standardized prevalence of dia-
betes in adults aged 20–79 years has been estimated
at 8.3% in 2011, and is projected to increase to
9.9% by 2030.[2] The majority of individuals with
diabetes (90%) have type 2 diabetes mellitus,[3]
a progressive disease characterized by pancreatic
b-cell dysfunction and increased insulin resis-
tance.[1] Epidemiological data on diabetes by age
group are limited, but US data indicate that the
prevalence of diabetes is high among the elderly.
In the US, the prevalence of diabetes increased
by 62% from 1994 to 2003 among individuals
>65 years of age.[4] It was estimated that 10.9million
individuals (26.9%) aged ‡65 years within the US
had diabetes in 2010.[5]
Hyperlipidaemia is a major risk factor for car-
diovascular complications in patients with type 2
diabetes, regardless of age.[6,7] Hyperlipidaemia
in patients with type 2 diabetes is associated with
high atherogenic risk and is characterized by el-
evated triglyceride levels, low high-density lipo-
protein cholesterol (HDL-C) levels, and a shift
towards small, dense, low-density lipoprotein par-
ticles.[6,8-10] Although low-density lipoprotein cho-
lesterol (LDL-C) levels in patients with diabetes
are generally similar to those in the general pop-
ulation,[8] patients with diabetes can benefit from
LDL-C reduction, even in the absence of ele-
vated LDL-C levels.[11] In addition, data from the
Framingham Heart Study indicate that hyperli-
pidaemia, obesity and cardiovascular disease of-
ten precede the development of type 2 diabetes in
older patients.[12] The overall prevalence of hyper-
lipidaemia (defined as an LDL-C level above that
recommended by the National Cholesterol Edu-
cation Program [NCEP] Adult Treatment Panel
III [ATP III] {i.e. <160mg/dL for patients with
0–1 risk factor, <130mg/dL for those with mul-
tiple risk factors, and <100mg/dL for those with
coronary heart disease and coronary heart dis-
ease risk equivalents[13]} or treatment with a li-
pid-lowering agent) has been reported to be as
high as 60.3% in patients aged ‡65 years.[14]
Although many treatments exist for control of
glucose and lipid levels in patients with type 2
diabetes, some are contraindicated in the pre-
sence of conditions that may be prevalent in the
elderly. In addition, some treatments are asso-
ciated with an increased risk of adverse effects in
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the general population and, to a greater degree, in
elderly patients. It is important to tailor treat-
ment to the needs of individual patients with type
2 diabetes, especially those who are elderly, in
order to improve outcomes.[15] The bile acid se-
questrant colesevelamHCl is an established treat-
ment for lowering LDL-C levels in adults with
primary hyperlipidaemia, but is not considered first-
line lipid-lowering therapy in adults with diabetes,
since statins are recommended first.[1] Coleseve-
lam is approved in the US for use in combination
with a statin, and could be used in patients with
diabetes who require LDL-C lowering beyond
that achieved with a statin. Colesevelam is also
approved in Canada, the EU, Iceland and Norway
for the treatment of hypercholesterolaemia. In
January 2008, colesevelam was also approved by
the US Food and Drug Administration (FDA)
for improving glycaemic control in adults with
type 2 diabetes.[16] In this review, the challenges
associated with controlling hyperglycaemia and
hyperlipidaemia in elderly patients are discussed,
with a focus on colesevelam in the context of tar-
geting appropriate glycaemic and lipid-lowering
goals in the elderly population. This non-systematic
review of the treatment of elderly patients with
type 2 diabetes is based on manual literature
searches.
2. Managing Hyperglycaemia and
Hyperlipidaemia in the Elderly
Treatment of diabetes (type 1 or type 2) is
often suboptimal, particularly in those aged
‡65 years.[14,17] Data from the National Health
and Nutrition Examination Survey from 1999 to
2004 indicate that 50.9% of elderly patients with
diabetes (type 1 or type 2) are treated phar-
macologically; however, only 50.4% of treated
patients achieve glycaemic control (defined as
haemoglobin A1c [HbA1c] <7.0%).[14] Recent clini-
cal trials in the type 2 diabetes patient population
have been unable to show reduced cardiovascular
events with aggressive HbA1c targets.
[18] The low
percentage of elderly patients who received phar-
macological treatment may be due to a range
of issues relating to perceived vulnerability, co-
morbidity, tolerability, polypharmacy, less aggressive
glycaemic targets and psychosocial issues.[14,15,19]
Similarly, only 64.9% of elderly patients who re-
ceived treatment to manage their hyperlipidae-
mia achieved the NCEP ATP III-recommended
target LDL-C level.[14]
2.1 Hyperglycaemia
The American Diabetes Association (ADA), the
American Association of Clinical Endocrinologists
(AACE) and the International Diabetes Federa-
tion (IDF) recommend HbA1c targets of <7.0%,
£6.5% and <6.5%, respectively, in all non-pregnant
adults with diabetes, although the ADA recom-
mends that the goals be individualized on the
basis of a number of factors, including age/life
expectancy.[1,20,21] Less intensive glycaemic targets
(e.g.HbA1c <8.0%) are recommended in older adults
with limited life expectancy, advanced diabetes
complications and/or cardiovascular disease.[18,22]
Alternatively, a significant minority of elderly
patients with longer life expectancy might benefit
from intensive management of hyperglycaemia
with a target HbA1c of <7.0%.[1,18,23] A study eval-
uating the implementation of American Geriatrics
Society guidelines recommending an HbA1c tar-
get of <8.0% in frail older adults (aged ‡55 years)
found that patients had fewer hyperglycaemic
episodes, lower HbA1c values and greater use of
glucose-lowering agents, but also found that there
was a significant increase in the incidence of severe
hypoglycaemia during the early implementation
period.[24]
2.2 Hyperlipidaemia
Although primary hyperlipidaemia has spe-
cific typical characteristics, studies suggest that
the benefit derived from lipid-lowering therapy
with anHMG-CoA reductase inhibitor (statin) in
terms of cardiovascular outcomes is comparable
in patients with and without diabetes (type 1 or
type 2).[8] The HPS (Heart Protection Study) and
the CARDS (Collaborative Atorvastatin Diabetes
Study) demonstrated that treatment with simvasta-
tin or atorvastatin, respectively, significantly re-
duced the risk of cardiovascular events in patients
with diabetes (type 1 or type 2 in the HPS and
type 2 in the CARDS).[25,26] Furthermore, results
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from the HPS indicated that the reduction in risk
of cardiovascular events reportedwith statin therapy
was similar in patients with and without diabetes
(type 1 or type 2).[25] A meta-analysis of clinical
studies evaluating statin therapy showed that patients
with diabetes who were aged £65 and >65 years
benefited to a similar extent from LDL-C lower-
ing regardless of baseline lipid profile.[27]
Lipid-lowering targets for patients with type 2
diabetes or at cardiometabolic risk are shown in
table I.[1,20,21,28] Slight variation exists among
targets advocated by the ADA, NCEP, AACE and
IDF for patients with type 2 diabetes,[1,20,21] and
those recommended by the ADA/American College
of Cardiology Foundation (ACCF) for patients
at cardiometabolic risk.[28] Treatment guidelines
often do not provide separate recommendations
for elderly patients; however, treatment in elderly
patients should be individualized on the basis
of physiological/functional age.[30] The ADA re-
commends statin treatment in all patients with
diabetes who have established cardiovascular dis-
ease, or those without cardiovascular disease
and at least one cardiovascular risk factor who
are >40 years of age, irrespective of baseline lipid
values.[1]
Although the association between hyperlipi-
daemia and cardiovascular risk weakens with age,
older patients have a higher baseline risk because
of other risk factors, and may benefit more from
lipid-lowering treatment.[31] Therefore, those expec-
ted to survive >1 year should be strongly considered
for primary and secondary prevention efforts as re-
commended by the NCEP and ADA.[1,13]
3. Safety/Adherence Concerns in Elderly
Patients with Type 2 Diabetes
The risk of hypoglycaemiawith glucose-lowering
agents is higher in elderly patients with type 2 dia-
betes because of altered pharmacokinetics, impaired
metabolism, co-morbid conditions that can mask
hypoglycaemia, impaired perception or isolation
preventing early identification and treatment of
hypoglycaemia, poor nutrition, polypharmacy, and/
or cognitive impairment leading to non-adherence
(e.g. reduced dose interval or increased dose ta-
ken in error).[19,32]
Reduced renal and hepatic function can be
present in elderly patients,[33] and therefore, phar-
macological agents must be selected carefully
on the basis of where they are metabolized or
Table I. The American Diabetes Association (ADA), the National Cholesterol Education Program (NCEP), the American Association of
Clinical Endocrinologists (AACE) and the International Diabetes Federation (IDF) lipid targets in patients with type 2 diabetes mellitus, and the
ADA/American College of Cardiology Foundation (ACCF) lipid and lipoprotein targets in patients at cardiometabolic risk[1,20,21,28,29]
Guideline Lipid and lipoprotein targets (mg/dL)
LDL-C HDL-C Non–HDL-C TG ApoB



















IDF <95 >39 – <200 –







a Target as a secondary goal when TG levels are ‡200mg/dL; goal is 30mg/dL higher than LDL-C goal.
b Patients with known CVD or diabetes with at least one additional CVD risk factor.
c Patients with diabetes but no other CVD risk factors, or without diabetes or CVD but with at least two additional CVD risk factors.
ApoB =apolipoprotein B; CVD = cardiovascular disease; HDL-C= high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein
cholesterol; TG = triglyceride(s); – indicates no target specified.
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excreted from the body. Decreased renal function
slows the drug metabolized through the kidneys,
which can decrease drug clearance, resulting in
increased plasma concentrations, which can po-
tentially lead to adverse effects.[19] Consequently,
doses of pharmacological agents may need to be
adjusted in elderly patients. Congestive heart
failure (CHF) is most common in the elderly, and
diabetes is an independent predictor for CHF in
the elderly.[34-36] In addition, elderly patients with
type 2 diabetes often have other co-morbid con-
ditions, including hypertension, coronary artery
disease and hyperlipidaemia. The use of polyphar-
macy may lead to drug–drug interactions, altered
drug pharmacokinetics and adherence issues.[19]
Furthermore, difficulty swallowing, frailty and
reduced manual dexterity may make some drugs
more difficult to take.
4. Agents Used for the Treatment of Type 2
Diabetes in the Elderly
4.1 Agents Used for Managing
Hyperglycaemia
Current treatment options for glucose con-
trol in type 2 diabetes are shown in table II. Oral
glucose-lowering agents are widely used for the
treatment of type 2 diabetes to control blood
glucose levels. These agents include insulin se-
cretagogues, including sulfonylureas (glipizide,
glyburide and glimepiride) and meglitinides (re-
paglinide and nateglinide); biguanides (metformin);
thiazolidinediones (rosiglitazone and pioglitazone);
a-glucosidase inhibitors (acarbose); dipeptidyl
peptidase-IV (DPP-IV) inhibitors (linagliptin,
saxagliptin and sitagliptin); and bile acid seques-
trants (colesevelam). Injectable glucose-lowering
Table II. Summary of classes of glucose-lowering agents used in type 2 diabetes mellitus[19,23,37-42]







Sulfonylureas Oral Pancreas ~1–2 Effective as
monotherapy; AEs rare
Risk of hypoglycaemia higher
in elderly
Meglitinides Oral Pancreas ~0.5–1.5 Can be used in patients
with renal impairment
Risk of hypoglycaemia higher in
elderly
Biguanides Oral Liver (and muscle,
adipose tissue)
~1–2 Minimal risk of
hypoglycaemia
Gastrointestinal AEs, weight loss;
contraindicated in renal
disease/dysfunction
Thiazolidinediones Oral Muscle, adipose
tissue, possibly
pancreas
~1–1.5 Minimal risk of
hypoglycaemia
Cause bone loss and fractures,
especially in older women; increase
risk of myocardial infarction and may











Oral Pancreas, intestine ~0.5–0.8 Minimal risk of
hypoglycaemia




SC Pancreas, intestine ~0.5–1.0 Aid in weight loss for
patients who cannot
exercise
Weight loss could be detrimental to
frail, underweight patients





be adjusted to prevent
elevated blood glucose
levels
High risk of hypoglycaemia; use and
administration may be complex in
elderly
Bile acid sequestrants Oral Liver, intestine,
pancreas




AEs = adverse events; HbA1c= haemoglobin A1c; SC = subcutaneous.
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agents include glucagon-like peptide-1 (GLP-1)
analogues (exenatide and liraglutide) and insulin
(short and long acting). Traditionally, insulin is
initiated when elevated blood glucose levels persist
despite oral glucose-lowering therapy (generally
starting with basal insulin and then transitioning
to bolus insulin with meals) or when a patient
presents with HbA1c >9.0% and symptomatic
hyperglycaemia, regardless of whether they are
on treatment or are treatment-naive.[20]
4.1.1 Limitations of Glucose-Lowering Agents Used
in the Treatment of Elderly Patients with Type 2
Diabetes
There are a number of potential safety issues as-
sociated with the use of various glucose-lowering
agents that are relevant to elderly patients, which
are summarized in table II.[19,23,37-39]
Chronic use of thiazolidinediones may cause
bone loss, which can increase the risk of fractures,
especially in older women.[43-45] Both thiazolidine-
diones and meglitinides can be used in patients
with impaired renal function since these agents
are not metabolized via the kidney; however,
both classes of glucose-lowering agents require
monitoring of liver function, and should be used
with caution in patients with hepatic impair-
ment.[19] Rosiglitazone may increase the risk of
myocardial infarction.[46] In addition, thiazoli-
dinediones can cause or exacerbate CHF in some
patients; thus, monitoring for heart failure is re-
quired after initiating these drugs, and they
are contraindicated in patients with established
New York Heart Association functional class III
or IV heart failure.[40,46,47] Based on the potential
for rosiglitazone to increase cardiovascular risk, the
marketing authorization for rosiglitazone-based
medications in the EU has been suspended,[48]
and, in the US, the FDA has created a Risk Eval-
uation and Mitigation Strategy (REMS) pro-
gramme to restrict access and distribution and
monitor patients taking the medication.[49] Re-
cently, the FDA warned that use of pioglitazone
for >1 year may be associated with an increased
risk of bladder cancer, and therefore it should not
be used in patients with active bladder cancer and
should be used with caution in those with a his-
tory of bladder cancer.[50]
Metformin is contraindicated in patients with
renal disease or dysfunction (serum creatinine
levels of ‡1.5mg/dL in males or ‡1.4mg/dL in
females),[41] and may not be suitable in elderly
patients who are underweight or frail, those with
hepatic impairment or thosewithCHF.[37,51] Recent
recommendations on the use of metformin in pa-
tients with compromised renal function has sug-
gested their safe use down to an estimated glo-
merular filtration rate of 30mL/min/1.73m2.[52]
Gastrointestinal effects may occur with metfor-
min (metallic taste, anorexia, nausea, abdominal
pain and diarrhoea), acarbose (abdominal discom-
fort, increased formation of intestinal gas and di-
arrhoea) and colesevelam (primarily constipa-
tion).[53] The gastrointestinal issues associated
with metformin can be minimized by a slow ini-
tial titration as suggested by the ADA.[42]
The risk of hypoglycaemia with sulfonylureas
andmeglitinides is increased in the elderly, partic-
ularly in patients with renal impairment.[37] Al-
though data are limited regarding the use of
DPP-IV inhibitors in the elderly, DPP-IV inhibi-
tors appear to have benign tolerability profiles
and a low risk of hypoglycaemia; however, for
those agents that are renally excreted, dose ad-
justments are necessary in patients with renal
impairment.[37,54]
In the general adult diabetes population, a-
glucosidase inhibitor use is uncommon, and this
holds true in the elderly population, possibly as a
result of its minimal effectiveness compared with
other available glucose-lowering agents. In addi-
tion, a-glucosidase inhibitors are associated with
gastrointestinal effects (flatulence and diarrhoea),
should be avoided in patients with renal impair-
ment, and may increase the risk of hypoglycaemia
when combined with prandial insulin.[37]
Insulin use is complex and has a high risk of
hypoglycaemia if taken inappropriately; there-
fore, if glycaemic control is achievable without it,
insulin use should be avoided in elderly patients
who have reduced cognitive function or poor man-
ual dexterity.[37]
Some glucose-lowering agents affect weight.
Sulfonylureas and thiazolidinediones are both as-
sociated with weight gain.[55] The DPP-IV inhibi-
tors are generally weight neutral, but the GLP-1
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analogues are associated with significant weight
loss,[56,57] which, although useful in overweight or
obese elderly patients, might potentially be less
beneficial in frail elderly patients or patients with
a low body mass index at baseline.
4.2 Agents Used for Managing Primary
Hyperlipidaemia
Pharmacotherapy for the treatment of primary
hyperlipidaemia across various co-morbidities
focuses on statin therapy as first-line treatment,
but allows for the addition of other lipid-lowering
therapies depending on patient cholesterol values
and co-morbidities, and avoidance of drug–drug
interactions. Current treatment options for man-
aging the lipid profile in adults with type 2 dia-
betes are summarized in table III. These options
include statins, niacin, fibrates (gemfibrozil and
fenofibrate), bile acid sequestrants (colesevelam,
cholestyramine and colestipol), and cholesterol
absorption inhibitors (ezetimibe). Statins are the
first-line treatment for LDL-C lowering for all
patients, including those with type 2 diabetes;
however, their use may be restricted or contra-
indicated in some patients (e.g. because of drug–-
drug interactions).[1,8]
4.2.1 Limitations of Lipid-Lowering Agents Used in
the Treatment of Elderly Patients with Type 2
Diabetes
The limitations of lipid-lowering agents in el-
derly patients with type 2 diabetes are summar-
ized in table III.[30,38,58,59] Primary and secondary
prevention trials have demonstrated the efficacy
and tolerability of lipid-lowering therapy in el-
derly patients with hyperlipidaemia[60,61] and in
patients with type 2 diabetes,[6,10] but data in el-
derly patients with type 2 diabetes are limited.
There are a number of potential safety issues
associated with lipid-lowering therapy that are
relevant to elderly patients with type 2 diabetes.
In general, statins are well tolerated.[62,63] How-
ever, statin therapy has been associated with muscle
injury and hepatotoxicity. According to informa-
tion in the product labelling from controlled studies,
1–5% of patients receiving statins may develop
Table III. Summary of classes of lipid-lowering agents used in type 2 diabetes mellitus[30,38,58,59]





Oral Liver ﬂ LDL-C by 17–61%
ﬂTC by 11–48%
ﬂTG by 2–45%
› HDL-C by 2–16%
Low incidence of AEs Increased risk of myopathy
Niacin Oral Adipose tissue,
liver







Can decrease glycaemic control




Low incidence of AEs Contraindicated in patients with




Oral Intestine ﬂ LDL-C by 10–30%
ﬂTC by 10–25%
›TG by up to 23%
›HDL-C by 2–5%












Low incidence of AEs Use should be avoided in patients
with hepatic impairment
AEs = adverse events; HDL-C =high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; TC = total cholesterol;
TG = triglycerides; › = increases; ﬂ =decreases.
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myalgia, although the incidence of this is not
significantly different to that in patients given
placebo.[62] A review of a drug safety database,
Qscan-FDA (DrugLogic, Inc., Reston, VA, USA),
from January 1990 through to March 2002 iden-
tified 3339 cases of statin-associated rhabdo-
myolysis.[62] A subsequent analysis of data from
November 1997 to March 2000 identified 612 cases
of rhabdomyolysis, with one-half of the reported
cases occurring in patients aged 51–75 years.[62]
Concomitant use of gemfibrozil and niacin were
found to increase the risk of statin-associated
myopathy (primarily associated with statins that
have a drug–drug interaction with gemfibrozil,
including lovastatin, simvastatin and rosuvasta-
tin).[62,64] In June 2011, the FDA initiated label
changes for products containing simvastatin to
include restrictions on the use of a simvastatin
dose of 80mg/day, because of an elevated risk of
myopathy at this dosage.[65] The FDA recom-
mends that simvastatin 80mg/day should only be
used in patients who have already taken this dose
for ‡12 months without evidence of myopathy.
Combination therapy may be a safer alternative
to help patients achieve LDL-C goals without
requiring high statin dosages such as these. Ele-
vated liver enzyme levels during statin treatment
are not uncommon, but studies have suggested
that the incidence of aminotransferase levels of
>3 times the upper limit of normal is approxi-
mately 1–3%, and is not significantly different
to that in patients given placebo.[66-70] The FDA
recently updated statin labels to recommend
performing liver enzyme tests before initiation of
therapy and as clinically indicated thereafter (as
opposed to routine periodic monitoring as was
previously recommended).[71] Importantly, there
does not appear to be an association between in-
creased age and risk of significant liver injury.[63]
The updated statin labels also include a warning
regarding reports of cognitive impairment asso-
ciated with statin use, which may be of particular
concern in elderly patients.[71]
Niacin has the potential to worsen glycaemic
control,[59] although studies have shown that
immediate-release niacin, as well as low doses of
extended-release niacin, can be used safely in pa-
tients with type 2 diabetes.[72-74] There are also
data suggesting that some statins may worsen
glycaemic control or increase the risk of new-
onset type 2 diabetes, as illustrated by findings
with atorvastatin.[75-77] Bile acid sequestrants
(colesevelam, cholestyramine and colestipol) are
associated with gastrointestinal effects, primarily
constipation.[78] Finally, the use of fibrates may
be limited in some elderly patients because they
are contraindicated in patients with hepatic or
severe renal impairment.[79,80]
4.3 Role of Colesevelam in Managing Lipid
and Glucose Levels
Bile acid sequestrants were initially approved
for reducing LDL-C levels. However, cholestyr-
amine and colesevelam have also been shown to
exert significant glucose-lowering effects in patients
with type 2 diabetes.[81-85] In 2008, colesevelam
received approval from the FDA for improving
glycaemic control in adults with type 2 diabetes.[16]
In addition to a tablet formulation, colesevelam
may be taken as an oral suspension, which may
be beneficial for elderly patients who may have
swallowing difficulties, and could facilitate pa-
tient adherence to treatment.
4.3.1 Efficacy
In three randomized, double-blind, placebo-
controlled studies, colesevelam significantly low-
ered mean HbA1c (treatment difference vs placebo:
-0.50% to -0.54%; p < 0.001 for all) and LDL-C
levels (-12.8% to -16.7%; p< 0.001 for all) in
adults with type 2 diabetes when added to stable
metformin-, insulin- or sulfonylurea-based ther-
apy.[83-85] A post hoc analysis on pooled data from
the three above-mentioned double-blind, placebo-
controlled studies (n= 1018) showed that coleseve-
lam significantly reduced the levels of mean HbA1c,
LDL-C, non–HDL-C and total cholesterol com-
pared with placebo in both the <65 and ‡65 years
of age subpopulations.[86,87] The effect of colese-
velam on cardiovascular morbidity and mortality
has not been established.
In addition, colesevelam has shown a dose-
sparing effect on statin therapy when used in com-
bination, but a statin dose potent enough to achieve
a 30–40% reduction in LDL-C levels should be
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targeted.[88-90] Therefore, combining colesevelam
with a moderate dose of a statin may be appro-
priate for adults who have not achieved lipid
targets with higher statin doses, or for adults who
may be susceptible to adverse effects when re-
ceiving a high dose of a statin.[59] However, adults
who require substantial LDL-C lowering may
still need to receive a high-potency statin dose,
either alone or in combination with additional
LDL-C-lowering agents.
4.3.2 Safety and Tolerability
Colesevelam is not systemically absorbed; there-
fore, the potential for systemic adverse events is
low, and patients receiving colesevelam do not
require routine monitoring of liver function. In
clinical studies, the overall incidence of adverse
events with colesevelam was similar to place-
bo.[83-85] Colesevelam has also been shown to be
weight neutral and have a low risk of hypogly-
caemia.[83-85] The most common adverse event
reported with colesevelam is constipation; clinical
studies have shown that the incidence of con-
stipation was higher with colesevelam compared
with placebo.[83-85] Constipation could be more
problematic for the elderly than for the general
population.[91]
However, colesevelam increased triglyceride
levels compared with placebo treatment (p< 0.001
when added to insulin- or sulfonylurea-based ther-
apy).[83-85] Similarly, in the age-based subgroup
analysis, triglyceride levels were significantly in-
creased with colesevelam treatment in both age
subgroups (colesevelam vs placebo treatment dif-
ference: <65 years, +14.7% [p < 0.0001]; ‡65 years,
+14.2% [p = 0.0036]).[87] A number of studies have
suggested an association between triglyceride le-
vels and cardiovascular risk; however, this is
controversial, with the effect size typically modest
compared with other cardiovascular risk factors
(including other lipid parameters).[92] In addition,
although triglyceride levels are closely associated
with type 2 diabetes, studies evaluating the asso-
ciation between triglycerides and cardiovascular
risk often do not include type 2 diabetes as a con-
founding factor.[92] Because colesevelam increases
triglyceride levels, it is contraindicated in patients
with triglyceride levels of >500mg/dL.[16]
5. Conclusions
The prevalence of type 2 diabetes is increasing
among elderly individuals in the US and world-
wide. Elderly patients with type 2 diabetes can be
difficult to treat because of co-morbidities and an
increased risk of adverse effects with pharmaco-
logical treatments. In addition, hyperlipidaemia
represents a particular health concern among el-
derly patients with diabetes. The proven efficacy,
once- or twice-daily dosing, and dual formula-
tions of the bile acid sequestrant colesevelam
make it a treatment option as an add-on to ex-
isting glucose-lowering therapy or lipid-lowering
statins for control of primary hyperlipidaemia
and hyperglycaemia in elderly patients with type
2 diabetes not achieving treatment targets. How-
ever, the effect of colesevelam on cardiovascular
morbidity and mortality has not been established.
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